Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444957 | 0.81 | MAPT (0.38) | POLBMAPT | |
| SCHEMBL10330355 | 0.81 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CIGLV6-57ALDH1A1 | |
| SCHEMBL25179575 | 0.78 | — | — | |
| SCHEMBL4767465 | 0.78 | MAPT (0.51) | ALDH1A1TDP1KDM4EMAPT | |
| SCHEMBL20957 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1KDM4EMEN1MAPT | |
| SCHEMBL523503 | 0.76 | HRH3 (0.36) | MEN1MAPTKMT2A | |
| SCHEMBL27674403 | 0.75 | PSMD14 (0.30) | ALDH1A1TDP1PSMD14CYP3A4TSHR | |
| SCHEMBL28822515 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TDP1KDM4EMEN1MAPT | |
| SCHEMBL2440172 | 0.75 | L3MBTL1 (0.42) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL8657449 | 0.75 | HTR2A (0.31) | ALDH1A1TDP1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781617-A4 | ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | claimed |
| CN-101023062-A | Production of alpha, beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-22 | — | — | CN | claimed |
| EP-1781617-A2 | ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| CN-1845901-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-11 | — | — | CN | claimed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| WO-2006004742-A2 | α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARAMCEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | claimed |
| JP-2006501194-A | — | — | 2006-01-12 | — | — | JP | claimed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | claimed |
| CN-1678587-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-05 | — | — | CN | claimed |
| EP-1525190-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-27 | — | — | EP | claimed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | claimed |
| US-20040067983-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | claimed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | claimed |
| EP-4127034-B1 | COMPOSITE POLYMERIC FILM | MYLAR SPECIALTY FILMS U S LP (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-115698150-B | Composite polymer film | 杜邦帝人薄膜美国有限合伙 | 2024-06-11 | — | — | CN | disclosed |
| US-20230340219-A1 | BREATHABLE COMPOSITE POLYMERIC FILMS | DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) | 2023-10-26 | — | — | US | disclosed |
| US-4120690-A | 2-Acylaminothiazol-4-ylacetamides as post-emergent selective herbicides | GULF OIL CORPORATION (US) | 1978-10-17 | — | — | US | disclosed |
| US-4078934-A | Photosensitive, image-forming composition containing a leuco 2,3-disubstituted-1-indanone and a photooxidant | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
| US-3992450-A | PHOTOSENSITIVE COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | ADRA2A 521/4885ADRA2B 418/4885ADRA2C 323/4885 |
| US-20040067983-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | ADRA2A 848/4885ADRA2B 658/4885ADRA2C 728/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | ADRA2A 178/4885ADRA2B 149/4885ADRA2C 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.